Tiny trial tracks experimental drug ABBV-932 in 8 healthy men
NCT ID NCT06953934
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This Phase 1 study will give a single dose of ABBV-932 (with a tiny radioactive marker) to 8 healthy men. The goal is to measure how the drug moves through the body, how long it stays, and how it is eliminated. Researchers will also check for any side effects. This is a safety and drug-processing study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Clinical Research /ID# 270490
RECRUITINGGroningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-932 (a drug being tested, given as an oral capsule with a radioactive tracer to track it)
What could go wrong
This is a very early, small study in just 8 healthy volunteers. It is designed to measure how the drug behaves in the body, not to treat any disease. There is no guarantee the drug will ever be tested in patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.